title: Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
abstract: Ferric citrate (Zerenex™, Keryx Biopharmaceuticals, Inc.), a phosphate binder drug candidate, recently completed a Phase III program confirming efficacy and demonstrating safety when used to treat hyperphosphatemia in patients with end-stage renal disease. Results of these trials demonstrate that ferric citrate effectively controls serum phosphorus and is well tolerated. Additionally, these studies demonstrate that ferric citrate improves iron parameters and reduces IV iron and erythropoietin stimulating agent utilization while maintaining hemoglobin levels. These unique features may further benefit the management of end-stage renal disease-related anemia.
authors.affiliation: Section of Nephrology, Rush University Medical Center, Chicago, IL, USA.
authors.forename: Marvin
authors.initials: M
authors.lastname: Sinsakul
authors.forename: Roger
authors.initials: R
authors.lastname: Rodby
authors.forename: Kausik
authors.initials: K
authors.lastname: Umanath
authors.forename: Robert
authors.initials: R
authors.lastname: Niecestro
authors.forename: Jamie P
authors.initials: JP
authors.lastname: Dwyer
mesh_terms: D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D002614:Chelating Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005290:Ferric Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D010710:Phosphates / Q000097:blood; D010758:Phosphorus / Q000097:blood
chemical_list: D002614:Chelating Agents; D005290:Ferric Compounds; D010710:Phosphates; D010758:Phosphorus; C025314:ferric citrate
keywords: anemia; end-stage renal disease; metabolic bone disease